TY - JOUR T1 - AugmentA: Patient-specific Augmented Atrial model Generation Tool JF - medRxiv DO - 10.1101/2022.02.13.22270835 SP - 2022.02.13.22270835 AU - Luca Azzolin AU - Martin Eichenlaub AU - Claudia Nagel AU - Deborah Nairn AU - Jorge Sánchez AU - Laura Unger AU - Olaf Dössel AU - Amir Jadidi AU - Axel Loewe Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/15/2022.02.13.22270835.abstract N2 - Digital twins of patients’ hearts are a promising tool to assess arrhythmia vulnerability and to personalize therapy. However, the process of building personalized computational models can be challenging and requires a high level of human interaction. A pipeline to standardize the generation of a patient’s atrial digital twin from clinical data is therefore desirable. We propose a patient-specific Augmented Atria generation pipeline (AugmentA) as a highly automated framework which, starting from clinical geometrical data, provides ready-to-use atrial personalized computational models. AugmentA consists firstly of a preprocessing step applied to the input geometry. Secondly, the atrial orifices are identified and labelled using only one reference point per atrium. If the user chooses to fit a statistical shape model (SSM) to the input geometry, it is first rigidly aligned with the given mean shape before a nonrigid fitting procedure is applied. AugmentA automatically generates the fiber orientation and finds local conduction velocities by minimizing the error between the simulated and clinical local activation time (LAT) map. The pipeline was tested on a cohort of 29 patients on both segmented magnetic resonance images (MRI) and electroanatomical maps of the left atrium. Moreover, the pipeline was applied to a bi-atrial volumetric mesh derived from MRI. The pipeline robustly integrated fiber orientation and anatomical region annotations in 38.4±5.7 s. The error between insilico and clinical LAT maps was on average 12.7 ms. In conclusion, AugmentA offers an automated and comprehensive pipeline delivering atrial digital twins from clinical data in procedural time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was performed on the supercomputer bwUniCluster 2.0 funded by the Ministry of Science, Research and Arts of Baden-Wuerttemberg and by the German Federal Ministry of Education and Research. This work was supported by European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No.766082 (MY-ATRIA project), the EMPIR programme co-financed by the participating states and from the European Union's Horizon 2020 research and innovation programme under grant MedalCare 18HLT07, and by Deutsche Forschungsgemeinschaft (DFG) (project ID 391128822, LO 2093/1-1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:From February to July 2019, 29 consecutive patients with symptomatic persistent AF (lasting >7 days and <12 months) scheduled for their first PVI were prospectively included in this clinical trial (German WHO primary registry DRKS, unique identifier: DRKS00014687). The study was approved by the institutional ethics committee of the University of Freiburg (Germany) and all patients provided written informed consent prior to enrollment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll personalized computational models used in this study including fiber orientation and anatomical labels are available online (https://doi.org/10.5281/zenodo.5589289). https://doi.org/10.5281/zenodo.5589289 ER -